Seeking Alpha


Send Message
View as an RSS Feed
View ajetjock's Comments BY TICKER:
Latest  |  Highest rated
  • FDA yanks tentative approval of Intellipharmaceutics's generic Focalin XR [View news story]
    This author is deliberately misleading and flat out lying with this title.

    The article has only one purpose: MANIPULATE the price down. Clearly illegal per SEC.

    As to smart investors they should be buying. IPCI has many more ANDAs and was recently granted faster track with Rexista. Hence saving tens of millions of Dollars for the company.

    This means, the company will be able to keep its float lean.

    Again, this is only a small blip while the Co. has multiple product baskets with several others awaiting approvals.

    None of which is mentioned in this manipulative, misleading and poorly written SPIN piece.
    Jun 22, 2015. 10:30 AM | Likes Like |Link to Comment
  • FDA yanks tentative approval of Intellipharmaceutics's generic Focalin XR [View news story]
    What a nonsense SPIN !

    Either the author does not even UNDERSTAND what he reads or he is just trying a negative spin.
    Jun 18, 2015. 10:33 PM | 1 Like Like |Link to Comment
  • New chief at Synta Pharma [View news story]
    Actually, she was only the second CEO after the founding CEO was forced out. (He is yet to sell ANY of his shares BTW.)

    I'll second the "good riddance" ...

    As to the new CEO, and the rest of SNTA BOD and executive team members; VERY impressive background and track record of SUCCESS.

    Not to mention that NOT ONE of the insiders, had sold even one SNTA share...

    " Mr. Schor joined Synta as Executive Vice President and Chief Operating Officer in December 2014. Mr. Schor has over 15 years of leadership experience in biotechnology, medical devices, business development and private equity. Mr. Schor served as Vice President, Global Branded Products Business Development and Pipeline Management at Teva Pharmaceuticals and at leadership positions in several emerging private and public companies. Mr. Schor led licensing and M&A transactions valued at over $8 billion with GSK, Amgen, Pfizer, Merck KGaA, OncoGeneX and other companies. Mr. Schor was a Partner at Yozma Venture Capital where he led the foundation and growth of multiple therapeutic companies from inception to significant commercial success and exit. Mr. Schor holds a Master in Business Administration, a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA). "
    Apr 27, 2015. 10:17 AM | 4 Likes Like |Link to Comment
  • Synta Pharmaceuticals: The Good News And The Bad News [View article]

    First; I don't think we are going to remain under 2 for a long time.

    Likely we end up over 2 even today.

    Second; Which institution was the recipient of these offering shares gifted at 30% discount ?

    Once we find out, it will be very telling as to the true purpose of this recent "drill".

    Holding long.
    Mar 31, 2015. 12:20 PM | 2 Likes Like |Link to Comment
  • Update: Synta Pharmaceuticals Reports Q3 Earnings - Where I Went Wrong [View article]
    Thanks for the report Christopher !

    I agree. The risk-reward here and now is very favorable for investors.

    I listened to to the conf. call call and liked what I have heard.

    PPS will follow.
    Nov 7, 2014. 08:20 AM | 2 Likes Like |Link to Comment
  • SinoCoking: Promoted Chinese Reverse Merger Near Bankruptcy, -81.9% Downside, Strong Sell [View article]
    Easy to pick on a Chinese Co.

    I actually spoke multiple time with the previous US based PR Co. which is VERY reputable and is based in NYC. They do not just take on any client. They DID TRAVEL to China and investigated the SCOP operation and as a result took SCOK as a client and represented them throughout the hard days of mines moratorium.

    During the tough years, SCOK NEVER issued stock just to remain in business, like many US Cos do. The issuance recently, where the proceeds will be used for the syngas project, was the first time in years they have done so in a very long time.

    So now that the stock caught the SHORT SHARKS attention, with its rapid rise, we have the same nameless sharks picking on an "easy" target using easy FEAR tactics to drive the price down.

    Half truth, innuendos , smoke and mirrors, is what shorts do best, to ANY company.

    Especially a LOW FLOAT stock such as SCOK, where the price can be easily MANIPULATED.

    Most investors though can see through the SHORTS tricks and as a result this article did nor have much affect on the PPS.

    But...I am sure they will keep on trying using SAME "code words" to shake few more shares.

    Hopefully long term investors are smarter and can see through the SHORT'S smoke.
    Oct 8, 2014. 10:42 AM | 1 Like Like |Link to Comment
  • Nordic American Tankers Limited (NYSE:NAT) Announces Public Offering [View article]
    This is a shelf offering, which means...It is old news !
    The company previously filed the offering and now
    exercising what they have previously said they will do.
    Apr 7, 2014. 06:29 PM | Likes Like |Link to Comment
  • Celldex: Some Thoughts On Rindopepimut [View article]
    Frank /RP.

    I am with Larry on this one ! " There will be better opportunities to get into CLDX" next 6 months or so.

    Maybe that will be the time CLDX INSIDERS will start putting their cash where their research is.

    Just like SNTA, or percentage ownership in IPCI. As a side note, check the news (Few min ago) on SNTA !! Definitely gearing up for a DEAL . Aside of the new 'deal maker' they just hired, Claxton increased their stake to 33%.
    And that is aside from Claxton's Ex CEO Bruce's PERSONAL stake...

    I place my money with this guys ! Hopefully one of these days we will see a more serious insiders trend at CLDX as well.

    That'll be time I'll get back into CLDX.

    Take care
    Dec 20, 2013. 08:59 AM | Likes Like |Link to Comment
  • Provectus Finds New Oncology Idea In An Old Product [View article]
    Trying to do some DD on this stock and all I get is that PVCT consists of 4 employees; Its execs. And they have a suite number address in Knoxville.

    The Advisory Board . Just a list of names. Nothing more...

    HOW is the research done and WHERE ?!

    What I also find interesting is that for such a small company they have a HUGE numbers of shares already...122 M.

    Is there more substance to this co besides 4 guys with an annual salary of a million each, trying to sell something ?
    Dec 13, 2013. 03:04 PM | 2 Likes Like |Link to Comment
  • More Good News: Synta Pharmaceuticals Could Be A Triple Bagger [View article]
    Thanks for the article. Long SNTA as well.

    Sold my entire CLDX position.

    A LOT is already baked into CLDX's price . SNTA reminds me of back when CLDX was at single digits.

    Like you, I appreciate when SNTA management in a vote of confidence BUYS shares in the open market.

    A FAR CRY from CLDX's management which just sold shares they got awarded as OPTIONS..., right after the offering. That does not give me the warm and fuzzy.

    I rather see management like SNTA confident enough in their research and product, to buy in the open market.

    Thanks again.
    Dec 12, 2013. 05:47 PM | 2 Likes Like |Link to Comment
  • Don't Be Scared Off By Risks In The Cancer Biotech Space [View article]
    Does CNDO even have a drug after the recent Crohn's flop ?

    I will stick with CLDX as a FAR safer company/pipeline and potentially much better reward.

    After all it is all about the risk Vs the reward
    Nov 20, 2013. 01:47 PM | 2 Likes Like |Link to Comment
  • Northwest Biotherapeutics Poses Onyx Like Potential [View article]
    The article compares Ph 3 results !

    Did you miss that little nugget ?
    Nov 20, 2013. 11:24 AM | Likes Like |Link to Comment
  • Northwest Biotherapeutics Poses Onyx Like Potential [View article]
    I agree.

    Just asked the same question: How can even remotely compare CLDX' HUMAN trials to NWBO animal results ?!

    Anyone ?
    Nov 20, 2013. 11:07 AM | Likes Like |Link to Comment
  • Northwest Biotherapeutics Poses Onyx Like Potential [View article]
    Are you folks seriously compare CLDX's human results to NWBO ANIMALS trials ?

    Am I missing something ?
    Nov 20, 2013. 11:03 AM | Likes Like |Link to Comment
  • Expensive Himax Technologies Is A Short Candidate - For Now [View article]
    Here is what I find interesting aside from the fact that the writer is hiding behind the a rock somewhere: Usually if someone tosses such an article into a discussion over any stock, it gets BOTH sides to respond. In HIMX's case however, almost ALL responders are solidly on the LONG side and armed with FACTS.

    The author OTOH, is armed with smoke and mirrors. I seriously doubt he could convince anyone to short with his lack of factual evidence or logic.
    Oct 6, 2013. 09:59 AM | 4 Likes Like |Link to Comment